🇺🇸 Neoadjuvant chemoradiotherapy based on irinotecan in United States

Neoadjuvant chemoradiotherapy based on irinotecan (Neoadjuvant chemoradiotherapy based on irinotecan) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Neoadjuvant chemoradiotherapy based on irinotecan in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Neoadjuvant chemoradiotherapy based on irinotecan approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Neoadjuvant chemoradiotherapy based on irinotecan in United States?

Zhejiang Cancer Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.